Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2017

01-02-2017 | Original Article

Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance

Authors: S. Krishna Priya, Kishore Kumar, K. R. Hiran, M. R. Bindhu, Rohit. P. Nagare, D. K. Vijaykumar, T. S. Ganesan

Published in: International Journal of Clinical Oncology | Issue 1/2017

Login to get access

Abstract

Objective

The purpose of this study was to evaluate microvessel density (MVD) as assessed by C-type lectin 14A (CLEC14A), which is a new marker for endothelial cells, and compare its expression to CD31 and CD105 in epithelial ovarian cancer (EOC).

Methods

MVD was evaluated in tumors (n = 50) from patients with EOC who underwent primary surgery and in patients with EOC who received preoperative chemotherapy (n = 49) using immunohistochemistry with antibodies to CLEC14A, CD31 and CD105. The median duration of follow-up was 24.5 months (range 1−101 months). The effect of prognostic factors on event-free survival (EFS) and overall survival (OS) was assessed using the Cox regression model.

Results

The amount of residual disease was found to be an independent prognostic factor in multivariate analysis with respect to EFS (P = 0.009) and OS (P < 0.001). The mean MVD of CLEC14A (MVD = 6), in tumors from patients who underwent primary surgery, was significantly lower than that of CD31 (MVD = 25, P < 0.0001) and CD105 (MVD = 11, P = 0.018). However, there was no significant correlation between MVD as detected by these markers and clinical outcome. There was no expression of CLEC14A in tumors from patients who received preoperative chemotherapy and the MVD of CD31 and CD105 was significantly reduced (P = 0.001 and 0.006, respectively) in this set of patients.

Conclusion

This study demonstrates MVD as detected by CLEC14A in EOC. Treatment with chemotherapy reduces tumor blood vessels significantly. We suggest that CLEC14A may be a more specific endothelial marker to assess tumor angiogenesis.
Appendix
Available only for authorised users
Literature
1.
2.
Brekken RA, Li C, Kumar S (2002) Strategies for vascular targeting in tumours. Int J Cancer 100:123–130CrossRefPubMed
3.
Krishna Priya S, Nagare RP, Sneha VS et al (2016) Tumour angiogenesis−origin of blood vessels. Int J Cancer 139:729–735CrossRefPubMed
4.
5.
Weidner N (1993) Tumour angiogenesis: review of current applications in tumour prognostication. Semin Diagn Pathol 10:302–313PubMed
6.
He L, Wang Q, Zhao X (2015) Microvessel density as a prognostic factor in ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 16:869–874CrossRefPubMed
7.
Mura M, Swain RK, Zhuang X et al (2012) Identification and angiogenic role of the novel tumour endothelial marker CLEC14A. Oncogene 31:293–305CrossRefPubMed
8.
Rho S-S, Choi H-J, Min J-K et al (2011) CLEC14A is specifically expressed in endothelial cells and mediates cell to cell adhesion. Biochem Biophys Res Commun 404:103–108CrossRefPubMed
9.
Zhuang X, Cross D, Heath VL, Bicknell R (2011) Shear stress, tip cells and regulators of endothelial migration. Biochem Soc Trans 39:1571–1575CrossRefPubMed
10.
Ki MK, Jeoung MH, Choi JR et al (2013) Human antibodies targeting the C-type lectin-like domain of the tumour endothelial cell marker CLEC14A regulate angiogenic properties in vitro. Oncogene 32:5449–5457CrossRefPubMedPubMedCentral
11.
Zanivan S, Maione F, Hein MY et al (2013) SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumour angiogenic markers. Mol Cell Proteomics 12:3599–3611CrossRefPubMedPubMedCentral
12.
Noy PJ, Lodhia P, Khan K et al (2015) Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth. Oncogene. 34(47):5821–5831CrossRefPubMed
13.
Horak ER, Leek R, Klenk N et al (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120–1124CrossRefPubMed
14.
Parums DV, Cordell JL, Micklem K et al (1990) JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752–757CrossRefPubMedPubMedCentral
15.
Haruta Y, Seon BK (1986) Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 83:7898–7902CrossRefPubMedPubMedCentral
16.
Nassiri F, Cusimano MD, Scheithauer BW et al (2011) Endoglin (CD105): a review of its role in angiogenesis and tumour diagnosis, progression and therapy. Anticancer Res 31:2283–2290PubMed
17.
Li DY, Sorensen LK, Brooke BS et al (1999) Defective angiogenesis in mice lacking endoglin. Science 284:1534–1537CrossRefPubMed
18.
Rosen LS, Hurwitz HI, Wong MK et al (2012) A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res 18:4820–4829CrossRefPubMedPubMedCentral
19.
Karzai FH, Apolo AB, Cao L et al (2014) A phase I study of TRC105 anti-CD105 (endoglin) antibody in metastatic castration-resistant prostate cancer. BJU Int 116(4):546–555CrossRef
20.
Gordon MS, Robert F, Matei D et al (2014) An open-label phase Ib dose-escalation study of trc105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res 20:5918–5926CrossRefPubMedPubMedCentral
21.
Costello B, Li C, Duff S et al (2004) Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer 109:436–441CrossRefPubMed
22.
Steg AD, Bevis KS, Katre AA et al (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18:869–881CrossRefPubMed
23.
Cox DR, Oakes D (1984) Analysis of Survival Data. Chapman and Hall, New York
24.
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457CrossRef
25.
Taskiran C, Erdem O, Onan A et al (2006) The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 16:1789–1793CrossRefPubMed
26.
Rubatt JM, Darcy KM, Hutson A et al (2009) Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol Oncol 112:469–474CrossRefPubMed
27.
Saad RS, Liu YL, Nathan G et al (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17:197–203CrossRefPubMed
28.
El-Gohary YM, Silverman JF, Olson PR et al (2007) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 127:572–579CrossRefPubMed
29.
Miyata Y, Sagara Y, Watanabe S et al (2013) CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34. Virchows Arch Int J Pathol 463:673–679CrossRef
30.
Dales J-P, Garcia S, Bonnier P et al (2003) CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol 119:374–380CrossRefPubMed
31.
Rau K-M, Huang C-C, Chiu T-J et al (2012) Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Exp Ther Med 4:231–236PubMedPubMedCentral
32.
Sundar SS, Zhang H, Brown P et al (2006) Role of lymphangiogenesis in epithelial ovarian cancer. Br J Cancer 94:1650–1657PubMedPubMedCentral
33.
Cwiklnska A, Sobstyl M, Kwasniewski W, Bednarek W (2013) Microtissue density prognostic factor evaluation based on antigens CD34 and CD 105 in ovarian cancer patients. Ann Agric Environ Med 20:838–842PubMed
34.
Bock AJ, Tuft Stavnes H, Kærn J et al (2011) Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol 32:589–596CrossRefPubMedPubMedCentral
35.
Orre M, Lotfi-Miri M, Mamers P, Rogers PA (1998) Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary. Br J Cancer 77:2204–2209CrossRefPubMedPubMedCentral
36.
Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404CrossRefPubMed
37.
38.
Beresford MJ, Harris AL, Ah-See M et al (2006) The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 95:1683–1688CrossRefPubMedPubMedCentral
39.
Hollingsworth HC, Kohn EC, Steinberg SM et al (1995) Tumour angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33–41PubMedPubMedCentral
40.
Alvarez AA, Krigman HR, Whitaker RS et al (1999) The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5:587–591PubMed
41.
Abulafia O, Ruiz JE, Holcomb K et al (2000) Angiogenesis in early-invasive and low-malignant-potential epithelial ovarian carcinoma. Obstet Gynecol 95:548–552PubMed
42.
Huynh H, Teo CCM, Soo KC (2007) Bevacizumab and rapamycin inhibit tumour growth in peritoneal model of human ovarian cancer. Mol Cancer Ther 6:2959–2966CrossRefPubMed
43.
Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496CrossRefPubMed
44.
Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483CrossRefPubMed
Metadata
Title
Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance
Authors
S. Krishna Priya
Kishore Kumar
K. R. Hiran
M. R. Bindhu
Rohit. P. Nagare
D. K. Vijaykumar
T. S. Ganesan
Publication date
01-02-2017
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1033-6

Other articles of this Issue 1/2017

International Journal of Clinical Oncology 1/2017 Go to the issue

Original Article

Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire

Original Article

The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery

Original Article

A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial

Original Article

The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy

Introduction to Invited Review Articles

Japanese contribution to the field of sentinel lymph node biopsy for breast cancer patients: introduction to invited articles

Original Article

Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits